Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
Pinkerton JV, Simon J, Panay N, Seitz C, Parke S, Caetano C, Mellinger U, Haseli Mashhadi N, Haberland C, Atanackovic G, Holz C, Mao G, Morrison M, Nisius S, Schaefers M, Zuurman L.
Pinkerton JV, et al. Among authors: caetano c.
Menopause. 2024 Jun 1;31(6):522-529. doi: 10.1097/GME.0000000000002350. Epub 2024 Apr 3.
Menopause. 2024.
PMID: 38564691
Clinical Trial.